We further examined the prognostic value of MYL9 expression in tumor cells in different subgroups of patients with ESCC stratified according to tumor differentiation, T classification, and lymph node metastasis. This evidence concerns the gene MYL9 and metastatic malignant neoplasm in the lymph nodes.